Related Experiment Video
Updated: Jun 30, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
Published on: October 3, 2019
AMPKalpha2 counteracts the development of cardiac hypertrophy induced by isoproterenol
Elham Zarrinpashneh1, Christophe Beauloye, Audrey Ginion
1Université catholique de Louvain, Division of Cardiology, 55 Avenue Hippocrate, CARD5550, B-1200 Brussels, Belgium.
Abstract:
As AMP-activated protein kinase (AMPK) controls protein translation, an anti-hypertrophic effect of AMPK has been suggested. However, there is no genetic evidence to confirm this hypothesis. We investigated the contribution of AMPKalpha2 in the control of cardiac hypertrophy by using AMPKalpha2-/- mice submitted to isoproterenol. The isoproterenol-induced cardiac hypertrophy, measured by left ventricular mass and histological examination, was significantly higher in AMPKalpha2-/- than in WT animals. Moreover, the intensification of cardiac hypertrophy found in AMPKalpha2-/- mice can be linked to the abnormal basal overstimulation of the p70 ribosomal S6 protein kinase, an enzyme known to regulate protein translation and cell growth. In conclusion, this work shows that AMPKalpha2 plays a role of brake for the development of cardiac hypertrophy.
Related Concept Videos
cAMP-dependent Protein Kinase Pathways
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Cellular Adaptation II: Hypertrophy
Heart Failure II: Pathophysiology
GPCRs Regulate Adenylyl Cylase Activity
Two...
Antihypertensive Drugs: Action of β1 Blockers
